Proteinase K Market Size to Attain USD 10.93 Billion at 8.54% CAGR by 2034

The proteinase K market size is calculated at USD 5.23 billion in 2025 and is expected to reach around USD 10.93 billion by 2034, growing at a CAGR of 8.54% for the forecasted period.

Ottawa, Oct. 07, 2025 (GLOBE NEWSWIRE) -- The global proteinase K market size was valued at USD 4.82 billion in 2024 and is predicted to hit around USD 10.93 billion by 2034, rising at a 8.54% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

The development of the global biotechnology and life sciences area, with diverse research and development activities, is fueling the enhanced adoption of proteinase K. Moreover, growing utilization and demand for diagnostics, especially molecular diagnostics, including PCR and NGS, and a widespread crucial role in drug discovery, vaccine development, and the production of therapeutic proteins, are supporting the global proteinase K market growth. Also, major government initiatives and investments in healthcare and research are driving the broad application of proteinase K.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5774

The Proteinase K Market: Highlight

The proteinase K industry is poised to reach USD 4.82 billion in 2024.
Forecasted to grow to USD 10.93 billion by 2034.
Expected to maintain a CAGR of 8.54% from 2025 to 2034.
North America was dominant in the market share by 46% in 2024.
Asia-Pacific is expected to be the fastest-growing region during 2025-2034.
By form, the powder segment led the global market in 2024.
By form, the liquid segment is expected to grow at a rapid CAGR in the studied years.
By therapeutic area, the infectious diseases segment dominated the proteinase K market in 2024.
By therapeutic area, the neurology segment is expected to grow fastest in the upcoming years.
By application, the isolation & purification of genomic DNA & RNA segment held a major revenue share of the market in 2024.
By application, the in situ hybridization segment is expected to be the fastest-growing during 2025-2034.
By end-use, the biotech companies segment led the market in 2024.
By end-use, the academic institutions segment is expected to register the fastest growth over the projected period.

Market Overview

Proteinase K is a serine protease with a wide range of specificity, highly employed in molecular biology for digesting proteins and nucleic acid extraction. The global proteinase K market is driven by escalating usage in molecular biology, diagnostics, and biopharmaceutical research. In 2025, the market will encompass several developments, such as the growth of recombinant and thermostable Proteinase K applications, strategic collaborations, and enhanced adoption in various sectors like forensic, clinical, and environmental testing.

Market Scope

Metric	Details
Market Size in 2025	USD 5.23 Billion
Projected Market Size in 2034	USD 10.93 Billion
CAGR (2025 - 2034)	8.54	%
Leading Region	North America share by 46%
Market Segmentation	By Form, By Therapeutic Area, By Application, By End-Use, By Region
Top Key Players	ACROBiosystems, Canvax Biotech, CDH Fine Chemical, ELK Biotechnology, Glentham Life Sciences, Magen Biotech, MagGenome, Meridian Bioscience, Minerva Biolabs, Inc., Sigma Aldrich, Takara Bio, TransGen Biotech Co. Ltd., Worthington Biochemical

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Crucial Adoption in DNA and RNA Purification: Major Potential

For extracting and purifying nucleic acids, i.e., DNA and RNA derived from different biological samples, consisting of cells and tissues, for use in downstream applications, such as PCR and sequencing, proteinase K plays an important role. On the other hand, the global proteinase K market has one more application is the application of proteinase K in in situ hybridization to discard unnecessary proteins that may interfere with the hybridization process, enabling more precise and sensitive detection of specific DNA or RNA sequences.

Maintenance of Quality and Supply Chain Concerns: Major Challenges

Due to variations in proteinase K quality from various providers, alongside limited availability, mainly in broader demand for DNA/RNA extraction, this can create a barrier in research and development. Besides this, economic and geopolitical uncertainties associated with potential tariff alterations can disturb supply chains and accelerate expenses for manufacturers and end-users.

The Proteinase K Market: Regional Analysis

Region	2024 Market Share (%)
North America	46	%
Europe	25	%
Asia Pacific	23	%
Latin America	4	%
Middle East and Africa	2	%

In 2024, North America held a major revenue share of 46% in the market. The presence of robust biotechnology and pharmaceutical industries, wider scientific research and innovation activities, and advanced healthcare infrastructure. Certainly, the market is expanding from a rise in demand in molecular biology, genomics, and proteomics, as well as diagnostic testing. Besides this, numerous ongoing collaborations among these leading companies are fostering this region’s market growth.

The U.S.’s increasing awareness and versatility of this enzyme in degrading proteins and facilitating DNA/RNA extraction make it a vital tool in continuous research and diagnostic settings. Whereas, the progressing demand for tailored treatments and targeted therapies relies on genomic and proteomic information, boosting the demand for proteinase K in cancer research and biomarker identification.

For instance,

In January 2025, CD Bioparticles, an established drug delivery company, unveiled its comprehensive line of Silica Spin Columns developed for efficient and reliable isolation of DNA & RNA, such as genomic DNA, cfDNA, plasmid DNA, and pathogenetic DNA & RNA.

In Canada, proteinase K is widely incorporated in molecular diagnostics, particularly in PCR and qPCR workflows is propelling the proteinase K market. Raised emphasis on accelerating areas, like genomics and proteomics, which are heavily dependent on proteinase K for sample preparation and analysis, is fueling its market growth.

Download the single region market report @ https://www.towardshealthcare.com/price/5774

The Asia Pacific is Predicted to Expand at the Fastest CAGR During 2025-2034

In the upcoming years, the Asia Pacific will show rapid expansion in the market. Primarily, widespread investments in healthcare infrastructure and biotechnology research, especially in countries like China, Japan, and India, are boosting the demand for proteinase K. Apart from this, the contribution of local enzyme producers in countries like China is also influencing the proteinase K market in ASAP by giving rise to inexpensive recombinant Proteinase K, boosting its accessibility.

In China, the wider adoption of PCR and NGS technologies is expanding various biotechnology companies, and a vast demand for novel vaccine candidates is driving the overall market expansion. Hence, China is considered a major hub for vaccine development and other products derived from nucleic acids.

For instance,

In August 2024, Zymo Research Corp., a pioneer in biotechnology, launched the Quick-DNA/RNA™ Water Kit to offer reliable total DNA/RNA recovery from water samples, developing a high standard in water sample preparation for sensitive downstream applications.

The Indian market is propelled by the emergence of different Indian suppliers like HiMedia, IndiaMART, and MagGenome, among others. They are usually utilized for isolating nucleic acids, removing proteins from samples, and other applications where protein degradation is essential.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

The Proteinase K Market: Segmentation Analysis

By form analysis

The powder segment registered dominance in the global market in 2024. Due to the major benefits of this form in the market, including its long-term stability, which assists in the maintenance of enzymatic activity during storage and transportation. As well as they also possess a longer shelf life as compared to other forms, and they can be shipped at affordable prices without the need for special temperature controls. Moreover, convenient to store and handle, the emergence of its versatility in powder form is impacting the ultimate market expansion.

On the other hand, the liquid segment is estimated to witness the fastest growth in the proteinase K market. Mainly, this liquid form diminishes the need for solubilization, conserves time in laboratory workflows. Along with this, the liquid form approaches are increasingly suitable for high-throughput processes and large-scale production, further driving their adoption. Also, ready-to-use liquid formulations reduce the risk of sample contamination, important for sensitive molecular applications.

By therapeutic area analysis

In 2024, the infectious diseases segment held a major revenue share of the proteinase K market. Primarily, proteinase K is highly applied in the RNA extraction step of COVID-19 diagnostic tests to discard proteins and RNases, ensuring accurate detection of the viral RNA. Furthermore, it is incorporated in the identification of pathogens like SARS-CoV-2, influenza viruses, noroviruses, and hepatitis viruses in diverse samples. It also supports the study of prion diseases by digesting proteins and enabling researchers to detect and analyze misfolded prion proteins.

However, the neurology segment will expand rapidly during 2025-2034. The development of new therapies for neurological disorders, comprising small-molecule drugs, enzyme replacements, gene editing, and gene therapy, is mainly fueling the market's expansion in the neurology segment. Apart from this, proteinase K is applied in DNA and RNA extraction from brain tissue, PCR purification, and removal of enzymes from DNA for cloning.

By application analysis

In the global proteinase K market, the isolation & purification of genomic DNA & RNA segment was dominant in 2024. Proteinase K has widespread proteases that cover a broader proteins, such as those are interfere with DNA and RNA. It also efficiently inactivates nucleases (DNases and RNases) present in the sample, with significant protection for them from degrading the DNA and RNA during the extraction and purification steps.

Moreover, the in situ hybridization segment is predicted to grow rapidly. Ongoing research in molecular pathology and diagnostics, as well as it is a major component in detecting patient-specific genetic alterations, which is vital for developing targeted therapies. A wide range of applications of ISH, like the combination use of both RNA (ISH) and protein (IHC), and whole-mount ISH, especially in developmental biology studies, are fueling the segment expansion.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Ongoing Developments in the In Situ Hybridization Segment

Company	Latest Developments
Leica Biosystems (April 2025)	Made a partnership with Bio-Techne to allow protease-free workflows for automated spatial multiomics on the BOND RX research staining instrument.
Biocare Medical (January 2025)	Collaborated with Molecular Instruments to transform automated bioimaging through ONCORE Pro X and HCR™ RNA-ISH assays.
Roche (June 2024)	Launched the foremost clinically approved, highly sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark.

By end-use analysis

The biotech companies segment held the dominating share of the global proteinase K market in 2024. The segment is driven by the vast usage of proteinase K to discard unnecessary proteins during the manufacturing of therapeutic proteins, vaccines, and other biologics. Also, further proteinase K is merged into mitochondria isolation, endotoxin removal, and protein footprinting. Mainly, nowadays, growing investments in drug discovery development and demand for customized demand in various severe health conditions are boosting the segment development.

And, the academic institutions segment will grow at a rapid CAGR in the market. Worldwide, progressing heavy R&D investments, particularly in genomics, microbiology, and molecular biology, are assisting in the demand for proteinase K in academic institutions. Alongside, broad collaborations among academic institutions and biotechnology companies are fostering novel developments in new applications for proteinase K. And, consistent breakthroughs in gene therapy and gene testing are propelling the adoption of these enzymes.

Browse More Insights of Towards Healthcare:

The global oral proteins and peptides market is valued at US$ 8.05 billion in 2024, rising to US$ 9.36 billion in 2025, and is expected to reach approximately US$ 36.35 billion by 2034, expanding at a CAGR of 16.34% from 2025 to 2034.

The global host cell protein testing market is valued at USD 2.37 billion in 2024, projected to increase to USD 2.56 billion in 2025, and further reach USD 5.19 billion by 2034, growing at a CAGR of 8.17% between 2025 and 2034.

The global cell-free protein expression market stands at USD 315.03 million in 2024, growing to USD 342.25 million in 2025, and anticipated to reach USD 716.26 million by 2034, expanding at a CAGR of 8.63% during 2025–2034.

The global protein therapeutics market is estimated at US$ 375.3 billion in 2024, increasing to US$ 401.89 billion in 2025, and projected to reach US$ 740.07 billion by 2034, registering a CAGR of 7.08% throughout the forecast period.

The global protein engineering market is valued at US$ 3.08 billion in 2024, expected to rise to US$ 3.58 billion in 2025, and reach US$ 13.84 billion by 2034, advancing at a CAGR of 16.27% from 2025 to 2034.

The global PEGylated proteins market is estimated at USD 1.63 billion in 2024, projected to grow to USD 1.82 billion in 2025, and reach USD 4.95 billion by 2034, expanding at a CAGR of 11.74% during the forecast period.

The global recombinant proteins market is valued at USD 3.36 billion in 2025 and is expected to reach USD 8.08 billion by 2034, reflecting a CAGR of 10.24% from 2025 to 2034.

The global research-grade proteins market is projected at US$ 1.13 billion in 2024, increasing to US$ 1.31 billion in 2025, and reaching US$ 4.81 billion by 2034, growing at a CAGR of 15.57% between 2025 and 2034.

The global G-protein coupled receptors (GPCR) market is valued at US$ 3.86 billion in 2024, growing to US$ 4.06 billion in 2025, and projected to reach US$ 6.37 billion by 2034, registering a CAGR of 5.14% during the forecast period.

The global C-reactive protein (CRP) testing market is estimated at USD 5.58 billion in 2024, slightly rising to USD 5.6 billion in 2025, and expected to reach USD 5.75 billion by 2034, with a modest CAGR of 0.3% between 2024 and 2034.

The global plasma protein products market was valued at US$ 32.8 billion in 2023 and is projected to grow to US$ 72.9 billion by 2034, at a CAGR of 7.53% from 2024 to 2034.

The global recombinant lysyl endopeptidase market was valued at US$ 38 million in 2023 and is projected to reach US$ 67.06 million by 2034, expanding at a CAGR of 5.3% over the same period.

The global recombinant human hair keratin protein market is witnessing notable growth, with revenues expected to reach several hundred million dollars by 2034, reflecting a strong upward trajectory.

The global protein labeling market is expected to expand from USD 2.89 billion in 2025 to USD 6.02 billion by 2034, at a CAGR of 8.48% during 2025–2034.

The global protein expression technology market is estimated at USD 2.85 billion in 2024, projected to reach USD 3.05 billion in 2025, and further grow to USD 5.58 billion by 2034, registering a CAGR of 6.94% between 2025 and 2034.

Proteinase K Market Companies:

ACROBiosystems
Canvax Biotech
CDH Fine Chemical
ELK Biotechnology
Glentham Life Sciences
Magen Biotech
MagGenome
Meridian Bioscience
Minerva Biolabs, Inc.
Sigma Aldrich
Takara Bio
TransGen Biotech Co., Ltd.
Worthington Biochemical

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/price/5774

Latest Developments in the Proteinase K Market

In July 2025, Covaris, a PerkinElmer company and pioneer in sample preparation technologies, and Hamilton Company, a leading player in automation solutions, entered into a partnership to distribute and co-market the truXTRAC^® FFPE SMART Solution, powered by the Hamilton^® Sonication STAR liquid handler.
In July 2025, CD Formulation, a global provider of advanced small nucleic acid synthesis solutions, unveiled a tailored circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, coupled with advanced design and QC processes.
In January 2025, Applied BioCode, a leader in molecular diagnostics panel testing, announced a major expansion to its KingFisher™ Flex Nucleic Acid Purification System with BioCode® Gastrointestinal Pathogen Panel (GPP).

Proteinase K Market Segmentation

By Form

Powder
Liquid

By Therapeutic Area

Infectious Diseases
Diabetes
Oncology
Cardiology
Nephrology
Autoimmune Diseases
Neurology
Others

By Application

Isolation & Purification of Genomic DNA & RNA
In situ Hybridization
Mitochondria Isolation

By End-Use

Contract Research Organization
Academic Institutes
Biotechnology Companies
Diagnostic Laboratories

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5774

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.